25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
In October 2017, the Occupational Safety and Health Administration (OSHA) began enforcing its Crysta...
Read More >
Through the Supreme Decree N° 014-2019-MIMP, the Ministry of Women and Vulnerable Populations has re...
Read More >
Businesses in the construction industry face a range of labor and employment issues related to COVID...
Read More >
Every private construction project in Illinois will be affected by a new law, effective immediately....
Read More >
On January 31, 2020, Chief United States District Judge Kimberly J. Mueller enjoined California from...
Read More >
On September 8, 2020, the new Agency for the Protection and Development of Competition (the “Agency...
Read More >